Biocept to Present Recent Advances in Biomarker Identification from Liquid Biopsies at GTCbio's 11th Biomarker Summit
"In these data sets, we demonstrate the ability of our circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) platforms to detect predictive and prognostic biomarkers from a simple blood sample, which can help physicians select personalized treatment regimens for their patients with cancer," said Dr. Pircher. "Our liquid biopsy assays can be particularly useful when there is insufficient sample material to perform a tissue biopsy or when a tissue biopsy has proven inadequate for identifying actionable biomarkers required to support the use of targeted drug therapy."
"We look forward to showcasing the capabilities of our liquid biopsy technology at this year's Biomarker Summit," stated
About Biomarker Summit 2018
Sponsored by GTCbio, Biomarker Summit 2018 is a meeting place for scientists and researchers to discuss all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization. A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Through scientific presentations, case studies and panel discussions, these areas will be addressed in an interactive environment with perspectives from industry, academia and the public.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis and treatment of cancer, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-to-present-recent-advances-in-biomarker-identification-from-liquid-biopsies-at-gtcbios-11th-biomarker-summit-300616160.html
Investor: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100; or Media: Trevelino/Keller, Colleen Murphy, Cmurphy@trevelinokeller.com, 404-214-0722, Ext. 109